Table 1 Characteristics of the ankylosing spondylitis study population
Total group | Validity study | Reliability study | |
|---|---|---|---|
Number of patients | 115 | 63 | 52 |
Age (years) | 44.6 ± 12.1 | 43.2 ± 12.3 | 46.3 ± 11.8 |
Gender (male) | 71 (62) | 40 (64) | 31 (60) |
Body mass index | 26.4 ± 4.4 | 26.2 ± 4.8 | 26.6 ± 3.9 |
Duration of symptoms (years) | 16 (0 to 54) | 18 (2 to 54) | 16 (0 to 53) |
Time since diagnosis | 10 (0 to 42) | 11 (1 to 42) | 9 (0 to 37) |
HLA-B27+ | 82 (76) | 49 (82) | 33 (69) |
Anti-TNF use | 78 (70) | 39 (62) | 39 (81)* |
NSAID use | 44 (40) | 24 (39) | 20 (42) |
DMARD use | 17 (15) | 13 (21) | 4 (8) |
BASDAI (range 0 to 10) | 3.7 (0.0 to 9.0) | 3.8 (0.4 to 8.6) | 3.5 (0.0 to 9.0) |
ESR (mm/hour) | 11 (2 to 60) | 13 (2 to 60) | 10 (2 to 39) |
CRP (mg/l) | 3 (2 to 46) | 3 (2 to 44) | 4 (2 to 46) |
ASDASCRP | 2.3 (0.7 to 4.4) | 2.3 (0.9 to 4.2) | 2.3 (0.7 to 4.4) |
BASFI (range 0 to 10) | 3.8 ± 2.4 | 3.6 ± 2.4 | 4.2 ± 2.4 |
Occiput-to-wall distance (cm) | 0.0 (0.0 to 29.0) | 0.0 (0.0 to 29.0) | 0.0 (0.0 to 20.0) |
Chest expansion (cm) | 5.0 (1.0 to 14.0) | 6.0 (1.0 to 10.5) | 4.0 (1.0 to 14.0)** |
Modified Schober test (cm) | 4.0 (0.4 to 7.0) | 4.0 (0.4 to 6.2) | 3.9 (0.0 to 7.0) |
Lateral spinal flexion (cm) | 10.0 (0.0 to 27.0) | 10.0 (0.0 to 25.0) | 10.0 (1.8 to 27.0) |
Cervical rotation (degrees) | 63 (5 to 98) | 70 (7 to 95) | 58 (5 to 98) |
ASQoL (range 0 to 18) | 6 (0 to 18) | 6 (0 to 17) | 6 (0 to 18) |